Curis Inc., a Lexington company developing small-molecule cancer drugs, said it will enter into a $30 million debt transaction, secured with certain future Erivedge royalties, with an investment fund managed by Pharmakon Advisors. Erivedge is the first and only US-approved medicine for people with advanced basal cell carcinoma, a press release said. It is developed and marketed by Genentech. The royalty payments that Curis will be entitled to under a collaboration with Genentech will be the source of funds to repay the loan.
Curis takes on $30 million worth of debt
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week